The management of MG with neuromuscular drugs in anesthesia is complex due to the altered sensitivity to both depolarizing and non-depolarizing neuromuscular blocking agents (NMBAs):
- Non-depolarizing NMBAs: Patients with MG are highly sensitive to these agents because the reduced number of functional AChRs makes it easier to achieve neuromuscular blockade with lower doses than usual. Therefore, anesthesia providers must use significantly reduced doses and closely monitor neuromuscular function to avoid profound and prolonged blockade.
- Depolarizing NMBAs (e.g., Succinylcholine): MG patients may exhibit resistance to depolarizing agents due to the decreased density of AChRs. This resistance can require higher doses to achieve effective neuromuscular blockade. However, the use of succinylcholine is also associated with a risk of triggering a myasthenic crisis due to excessive depolarization and subsequent desensitization of AChRs.
Given these considerations, careful preoperative assessment, judicious choice of neuromuscular blocking agents, and vigilant intraoperative monitoring are essential to safely manage patients with Myasthenia Gravis undergoing surgery.
